Changes in Body Composition Before and After Parkinson's Disease Diagnosis

2021 ◽  
Author(s):  
Shengfang Song ◽  
Zhehui Luo ◽  
Chenxi Li ◽  
Xuemei Huang ◽  
Eric J. Shiroma ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Body Composition ◽  
Disease Diagnosis ◽  
Before And After

Blood Cholesterol Decreases as Parkinson’s Disease Develops and Progresses

2021 ◽  
pp. 1-10
Author(s):  
Keran Wang ◽  
Zhehui Luo ◽  
Chenxi Li ◽  
Xuemei Huang ◽  
Eric J. Shiroma ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Confidence Interval ◽  
Total Cholesterol ◽  
Cholesterol Level ◽  
Disease Diagnosis ◽  
Inverse Association ◽  
Prodromal Stage ◽  
Before And After ◽  
Blood Total Cholesterol

Background: Literature shows an inverse association of circulating cholesterol level with the risk of Parkinson’s disease (PD); this finding has important ramifications, but its interpretation has been debated. Objective: To longitudinally examine how blood total cholesterol changes during the development of PD. Methods: In the Health, Aging and Body Composition study (n = 3,075, 73.6±2.9 years), blood total cholesterol was measured at clinic visit years 1, 2, 4, 6, 8, 10, and 11. We first examined baseline cholesterol in relation to PD risk, adjusting for potential confounders and competing risk of death. Then, by contrasting the observed with expected cholesterol levels, we examined the trajectory of changes in total cholesterol before and after disease diagnosis. Results: Compared to the lowest tertile of baseline total cholesterol, the cumulative incident ratio of PD and 95%confidence interval was 0.41 (0.20, 0.86) for the second tertile, and 0.69 (0.35, 1.35) for the third tertile. In the analysis that examined change of total cholesterol level before and after PD diagnosis, we found that its level began to decrease in the prodromal stage of PD and became statistically lower than the expected values∼4 years before disease diagnosis (observed-expected difference, –6.68 mg/dL (95%confidence interval: –13.14, –0.22)). The decreasing trend persisted thereafter; by year-6 post-diagnosis, the difference increased to –13.59 mg/dL (95%confidence interval: –22.12, –5.06), although the linear trend did not reach statistical significance (p = 0.10). Conclusion: Circulating total cholesterol began to decrease in the prodromal stage of PD, which may in part explain its reported inverse association with PD.

scholarly journals Beneficios de la actividad física durante un lapso de 16 semanas en pacientes con Enfermedad de Parkinson de la fundación “FUNDAPE”, Marzo–Septiembre 2019

2021 ◽  
Vol 13 (1) ◽  
pp. 33-39
Author(s):  
Rosa Susana Cajamarca Naula
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Body Composition ◽  
Oxygen Consumption ◽  
Aerobic Exercise ◽  
Disease Diagnosis ◽  
Motor Symptoms ◽  
Maximum Oxygen Consumption ◽  
The Mean ◽  
Non Motor Symptoms

BACKGROUND: Parkinson's disease (PD) is neurodegenerative, explained by the loss of dopaminergic neurons of the substantia nigra, affecting most commonly people over 60 years of age. The aim of this study was to analyze the benefits in both motor and non-motor symptoms, found after a 16-week pro- gram of physical activity in people with this disease who belong to the Parkinson Foundation of Ecuador (FUNDAPE). METHODS: This is a quasi-experimental interventional study, with a sample of 17 patients with Parkin- son’s disease diagnosis that went through a 16 week program of aerobic exercise, to analyze its impact on maximum oxygen consumption, motor skills, balance, cognition, body composition, and presence of depression. For the analysis, Wilconson “t-test” was applied. Confidence interval was 95%, 5% error. RESULTS: The maximum oxygen consumption improved 29.86%. The percentage of fat mass decreased 10.78%. The muscle weight percentage increased 4.58%. Regarding the different evaluated tests, the mean score for UPRDS improved 8.29%; the mean score for Berg Scale test improved 6.25%; regarding Ye- savage Geriatric Depression Scale, the percentage of patients with probable depression decreased from 42.86% to 7.14% in the group with PD of ≤5 years of evolution, and from 66.67% to 33.33% in the group with PD for than 5 years; regarding the Folstein Minimental State of Mind test, we found no benefits. CONCLUSION: This study showed that there are statistically significant benefits resulting from the appli- cation of a 16 week aerobic exercise program in patients with Parkinson’s disease, related to the motor and non-motor symptoms of the disease, body composition, and maximum oxygen consumption. No significant benefits were found in relation to the cognitive impairment associated with the disease. The benefits were greater in patients younger than 60 years of age, and were also greater in patients with less than 5 years of evolution of the disease.

Visual Effects of Deep Brain Stimulation in a Patient with Parkinson’s Disease

2019 ◽  
pp. 158-173
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Deep Brain Stimulation ◽  
Visual System ◽  
Brain Stimulation ◽  
Neurodegenerative Disorder ◽  
Initial Examination ◽  
Before And After ◽  
Deep Brain ◽  
Cover Test

Background: Parkinson’s disease (PD) is a progressive neurodegenerative disorder caused by a dopamine deficiency that presents with motor symptoms. Visual disorders can occur concomitantly but are frequently overlooked. Deep brain stimulation (DBS) has been an effective treatment to improve tremors, stiffness and overall mobility, but little is known about its effects on the visual system. Case Report: A 75-year-old Caucasian male with PD presented with longstanding binocular diplopia. On baseline examination, the best-corrected visual acuity was 20/25 in each eye. On observation, he had noticeable tremors with an unsteady gait. Distance alternating cover test showed exophoria with a right hyperphoria. Near alternating cover test revealed a significantly larger exophoria accompanied by a reduced near point of convergence. Additional testing with a 24-2 Humphrey visual field and optical coherence tomography (OCT) of the nerve and macula were unremarkable. The patient underwent DBS implantation five weeks after initial examination, and the device was activated four weeks thereafter. At follow up, the patient still complained of intermittent diplopia. There was no significant change in the manifest refraction or prism correction. On observation, the patient had remarkably improved tremors with a steady gait. All parameters measured were unchanged. The patient was evaluated again seven months after device activation. Although vergence ranges at all distances were improved, the patient was still symptomatic for intermittent diplopia. OCT scans of the optic nerve showed borderline but symmetric thinning in each eye. All other parameters measured were unchanged. Conclusion: The case found no significant changes on ophthalmic examination after DBS implantation and activation in a patient with PD. To the best of the authors’ knowledge, there are no other cases in the literature that investigated the effects of DBS on the visual system pathway in a patient with PD before and after DBS implantation and activation.

Pursuing Multiple Biomarkers for Early Idiopathic Parkinson’s Disease Diagnosis

2021 ◽  
Author(s):  
Yareth Gopar-Cuevas ◽  
Ana P. Duarte-Jurado ◽  
Rosa N. Diaz-Perez ◽  
Odila Saucedo-Cardenas ◽  
Maria J. Loera-Arias ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Disease Diagnosis ◽  
Idiopathic Parkinson’S Disease ◽  
Idiopathic Parkinson's Disease ◽  
Multiple Biomarkers

scholarly journals Holistic Metabolomic Laboratory-Developed Test (LDT): Development and Use for the Diagnosis of Early-Stage Parkinson’s Disease

Metabolites ◽  
2020 ◽  
Vol 11 (1) ◽  
pp. 14
Author(s):  
Petr G. Lokhov ◽  
Dmitry L. Maslov ◽  
Steven Lichtenberg ◽  
Oxana P. Trifonova ◽  
Elena E. Balashova
Keyword(s):  
Parkinson’S Disease ◽  
Molecular Weight ◽  
Parkinson's Disease ◽  
High Resolution Mass Spectrometry ◽  
Early Stage ◽  
Disease Diagnosis ◽  
The Body ◽  
Low Molecular Weight ◽  
Low Molecular Weight Compounds

A laboratory-developed test (LDT) is a type of in vitro diagnostic test that is developed and used within a single laboratory. The holistic metabolomic LDT integrating the currently available data on human metabolic pathways, changes in the concentrations of low-molecular-weight compounds in the human blood during diseases and other conditions, and their prevalent location in the body was developed. That is, the LDT uses all of the accumulated metabolic data relevant for disease diagnosis and high-resolution mass spectrometry with data processing by in-house software. In this study, the LDT was applied to diagnose early-stage Parkinson’s disease (PD), which currently lacks available laboratory tests. The use of the LDT for blood plasma samples confirmed its ability for such diagnostics with 73% accuracy. The diagnosis was based on relevant data, such as the detection of overrepresented metabolite sets associated with PD and other neurodegenerative diseases. Additionally, the ability of the LDT to detect normal composition of low-molecular-weight compounds in blood was demonstrated, thus providing a definition of healthy at the molecular level. This LDT approach as a screening tool can be used for the further widespread testing for other diseases, since ‘omics’ tests, to which the metabolomic LDT belongs, cover a variety of them.

scholarly journals Evaluation of fecal microbiota transplantation in Parkinson's disease patients with constipation

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Xiao-yi Kuai ◽  
Xiao-han Yao ◽  
Li-juan Xu ◽  
Yu-qing Zhou ◽  
Li-ping Zhang ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Rating Scale ◽  
Neurodegenerative Disorder ◽  
Fecal Microbiota Transplantation ◽  
Fecal Microbiota ◽  
Motor Symptoms ◽  
Gastrointestinal Dysfunction ◽  
Before And After ◽  
Non Motor Symptoms

AbstractParkinson’s disease (PD) is a neurodegenerative disorder and 70–80% of PD patients suffer from gastrointestinal dysfunction such as constipation. We aimed to assess the efficacy and safety of fecal microbiota transplantation (FMT) for treating PD related to gastrointestinal dysfunction. We conducted a prospective, single- study. Eleven patients with PD received FMT. Fecal samples were collected before and after FMT and subjected to 16S ribosomal DNA (rDNA) gene sequencing. Hoehn-Yahr (H-Y) grade, Unified Parkinson's Disease Rating Scale (UPDRS) score, and the Non-Motion Symptom Questionnaire (NMSS) were used to assess improvements in motor and non-motor symptoms. PAC-QOL score and Wexner constipation score were used to assess the patient's constipation symptoms. All patients were tested by the small intestine breath hydrogen test, performed before and after FMT. Community richness (chao) and microbial structure in before-FMT PD patients were significantly different from the after-FMT. We observed an increased abundance of Blautia and Prevotella in PD patients after FMT, while the abundance of Bacteroidetes decreased dramatically. After FMT, the H-Y grade, UPDRS, and NMSS of PD patients decreased significantly. Through the lactulose H2 breath test, the intestinal bacterial overgrowth (SIBO) in PD patients returned to normal. The PAC-QOL score and Wexner constipation score in after-FMT patients decreased significantly. Our study profiles specific characteristics and microbial dysbiosis in the gut of PD patients. FMT might be a therapeutic potential for reconstructing the gut microbiota of PD patients and improving their motor and non-motor symptoms.

Color-convertible fluorescent nanoprobe for Parkinson’s disease diagnosis

2021 ◽  
pp. 132368
Author(s):  
Jiapei Yang ◽  
Lei Wang ◽  
Yue Su ◽  
Lingyue Shen ◽  
Xihui Gao ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Disease Diagnosis ◽  
Fluorescent Nanoprobe

Body composition in Parkinson’s disease: a study with dual-energy X-ray absorptiometry

1998 ◽  
Vol 4 (3) ◽  
pp. 137-142 ◽  
Author(s):  
Manuel Revilla ◽  
FélixJavier Jiménez-Jiménez ◽  
LuisFrancisco Villa ◽  
EmmaRosa Hernández ◽  
Miguel Ortı́-Pareja ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Body Composition ◽  
Dual Energy ◽  
X Ray
Sign in / Sign up

Export Citation Format

Share Document